Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy

Table 2

Relationship between the pretreatment PGR and AGR and clinicopathological factors.

	PGR			AGR
	Low	High	value	Low	High	value
Sex
Male	95	92	0.528	86	101	0.835
Female	44	50		42	52
Age (yr)
>60	63	59	0.523	61	61	0.190
≤60	76	83		67	92
Body mass index (kg/m^2)
<18.5 or >25	40	32	0.231	30	42	0.443
18.5–25	99	110		98	111
ECOG
0–1	113	120	0.474	104	129	0.497
≥2	26	22		24	24
Histological type
Papillary, tubular	35	38	0.763	27	46	0.088
Poorly cohesive, mucinous	104	104		101	107
TNM stage
III	26	29	0.717	21	34	0.221
IV	113	113		107	119
Number of organs affected by metastasis
0–1	90	100	0.309	78	112	0.029
≥2	49	42		50	41
Peritoneal metastasis
Yes	52	39	0.075	50	41	0.029
No	87	103		78	112
CEA (ng/mL)
>5	67	54	0.085	56	65	0.831
≤5	72	88		72	88
CA72-4 (U/mL)
>6	79	79	0.839	76	82	0.331
≤6	60	63		52	71
CA19-9 (U/mL)
>37	59	47	0.106	52	54	0.359
≤37	80	95		76	99
Hemoglobin (g/L)
<115	63	42	0.006	61	44	0.001
≥115	76	100		67	109

PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio; ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9.